Financial Gravity Asset Management’s Blueprint Medicines BPMC Stock Holding History

Financial Gravity Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4	Closed	-$362	–	1564
2024 Q1	$362	Buy	+4	New	+$343	﹤0.01%	1468
2023 Q3	–	Sell	-63	Closed	-$323	–	1302
2023 Q2	$323	Buy	+63	New	+$3.42K	﹤0.01%	1061
2023 Q1	–	Sell	-44	Closed	-$238	–	1193
2022 Q4	$238	Buy	+44	New	+$2.11K	﹤0.01%	905
2019 Q4	–	Sell	-1	Closed	–	–	1404
2019 Q3	$0	Buy	+1	New	+$86	﹤0.01%	1207
2018 Q3	$0	Buy	6 +2	+50%	+$139	﹤0.01%	1398
2018 Q2	$0	Buy	+4	New	+$318	﹤0.01%	1415

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Financial Gravity Asset Management's BPMC Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Blueprint Medicines (BPMC) in Q2 2024, closing a stake of 4 shares — an estimated $362 sold.

Financial Gravity Asset Management first reported a position in BPMC in Q2 2018 and held it in 6 quarters. The position peaked at $362 in Q1 2024. 305 funds tracked by Wall St. Rank hold BPMC as of Q2 2024.

Financial Gravity Asset Management reported no remaining Blueprint Medicines position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 4 Blueprint Medicines shares in Q2 2024, an estimated $362.
Financial Gravity Asset Management first reported a position in Blueprint Medicines in Q2 2018 and held it in 6 quarters.
Financial Gravity Asset Management's Blueprint Medicines position peaked at $362 in Q1 2024.
305 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.